$SAGE
Sage Therapeutics, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020050861 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3
Revenue $1.639M $3.570M
YoY Change -54.09%
Cost Of Revenue $100.0K $100.0K
YoY Change 0.0%
Gross Profit $1.500M $3.400M
YoY Change -55.88%
Gross Profit Margin 91.52% 95.24%
Selling, General & Admin $35.10M $88.50M
YoY Change -60.34% 64.83%
% of Gross Profit 2340.0% 2602.94%
Research & Development $74.10M $102.1M
YoY Change -27.43% 36.05%
% of Gross Profit 4940.0% 3003.18%
Depreciation & Amortization $700.0K $700.0K
YoY Change 0.0% 133.33%
% of Gross Profit 46.67% 20.59%
Operating Expenses $108.8M $190.7M
YoY Change -42.96% 48.16%
Operating Profit -$107.2M -$187.2M
YoY Change -42.75% 45.39%
Interest Expense $1.300M $7.200M
YoY Change -81.94% 23.78%
% of Operating Profit
Other Income/Expense, Net $100.0K $0.00
YoY Change -100.0%
Pretax Income -$105.7M -$180.0M
YoY Change -41.28% 46.46%
Income Tax
% Of Pretax Income
Net Earnings -$105.7M -$180.0M
YoY Change -41.24% 46.4%
Net Earnings / Revenue -6451.19% -5040.84%
Basic Earnings Per Share -$2.03
Diluted Earnings Per Share -$2.03 -$3.482M
COMMON SHARES
Basic Shares Outstanding 51.98M 51.70M
Diluted Shares Outstanding 51.98M 51.70M

Balance Sheet

Concept 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $670.9M $1.125B
YoY Change -40.34% 9.9%
Cash & Equivalents $186.6M $261.5M
Short-Term Investments $484.3M $863.1M
Other Short-Term Assets $30.30M $30.40M
YoY Change -0.33% 64.32%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $698.9M $1.153B
YoY Change -39.37% 10.85%
LONG-TERM ASSETS
Property, Plant & Equipment $7.404M $9.365M
YoY Change -20.94% 80.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.800M $3.818M
YoY Change 51.91% 100.95%
Total Long-Term Assets $39.70M $51.03M
YoY Change -22.2% 618.69%
TOTAL ASSETS
Total Short-Term Assets $698.9M $1.153B
Total Long-Term Assets $39.70M $51.03M
Total Assets $738.6M $1.204B
YoY Change -38.64% 14.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable -$24.90M $5.041M
YoY Change -593.95% -14.56%
Accrued Expenses $46.76M $78.13M
YoY Change -40.15% 491.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $59.70M $90.96M
YoY Change -34.36% 66.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $21.40M $340.0K
YoY Change 6194.12% -91.5%
Total Long-Term Liabilities $21.40M $340.0K
YoY Change 6194.12% -91.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $59.70M $90.96M
Total Long-Term Liabilities $21.40M $340.0K
Total Liabilities $81.00M $122.7M
YoY Change -33.96% 109.67%
SHAREHOLDERS EQUITY
Retained Earnings -$2.000B -$1.475B
YoY Change 35.6% 83.23%
Common Stock $2.555B
YoY Change 42.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $657.6M $1.081B
YoY Change
Total Liabilities & Shareholders Equity $738.6M $1.204B
YoY Change -38.64% 14.97%

Cashflow Statement

Concept 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$105.7M -$180.0M
YoY Change -41.24% 46.4%
Depreciation, Depletion And Amortization $700.0K $700.0K
YoY Change 0.0% 133.33%
Cash From Operating Activities -$91.00M -$128.7M
YoY Change -29.29% 60.47%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$2.000M
YoY Change -100.0% 100.0%
Acquisitions
YoY Change
Other Investing Activities $13.50M $209.7M
YoY Change -93.56% 18963.64%
Cash From Investing Activities $13.50M $207.8M
YoY Change -93.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.600M 14.00M
YoY Change -74.29% 75.0%
NET CHANGE
Cash From Operating Activities -91.00M -128.7M
Cash From Investing Activities 13.50M 207.8M
Cash From Financing Activities 3.600M 14.00M
Net Change In Cash -73.90M 93.10M
YoY Change -179.38% -228.95%
FREE CASH FLOW
Cash From Operating Activities -$91.00M -$128.7M
Capital Expenditures $0.00 -$2.000M
Free Cash Flow -$91.00M -$126.7M
YoY Change -28.18% 59.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:CollaborativeArrangementMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:CollaborativeArrangementMember
CY2019Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:CollaborativeArrangementMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:CollaborativeArrangementMember
us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
true
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24168000
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2501000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-136347000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
739915000
CY2019Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2793000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30218000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2087000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-126740000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12436000
CY2019Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3946000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
43053000
CY2019Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
202000
CY2019Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-1483000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-179958000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
1081071000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
944655000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
367000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
849206000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
387000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2157000
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2144000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19863000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-763000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-105735000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
657581000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2000000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. <span style="Background-color:#FFFFFF;color:#212529;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including developments related to the scope and duration of the pandemic; the timing, extent and frequency of surges in the number of cases of COVID-19; new information that may emerge concerning COVID-19; and the actions taken to contain the COVID-19 pandemic. The Company has made estimates of the impact of the COVID-19 pandemic within its consolidated financial statements, and there may be changes to those estimates in future periods. </span>Actual results could differ from those estimates.</p>
CY2020Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
484267000
CY2020Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
668537000
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
126705000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
978000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
32000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
484267000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
880393000
CY2020Q3 sage Marketable Securities Held To Maturity Fair Value
MarketableSecuritiesHeldToMaturityFairValue
18900000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2019 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Depreciation
Depreciation
2000000.0
us-gaap Depreciation
Depreciation
1600000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13843000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13625000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6439000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4499000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7404000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9126000
CY2019Q3 us-gaap Depreciation
Depreciation
700000
CY2020Q3 sage Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
29233000
CY2019Q4 sage Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
46940000
CY2020Q3 sage Accrued Restructuring Expenses
AccruedRestructuringExpenses
1356000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9147000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22011000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6045000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
16720000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
975000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
947000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
46756000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
86618000
CY2020Q3 us-gaap Lessor Operating Lease Renewal Term
LessorOperatingLeaseRenewalTerm
P5Y
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5300000
CY2019 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-01-31
CY2020Q2 sage Remaining Amount Of Lease Write Off
RemainingAmountOfLeaseWriteOff
2300000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
986996
CY2019Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3833334
CY2019Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
150.00
CY2019Q1 sage Proceeds From Issuance Of Common Stock Net Of Offering Expenses
ProceedsFromIssuanceOfCommonStockNetOfOfferingExpenses
560900000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12580983
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4264646
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
550890
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
sage Stock Option Modification As Part Of Restructuring
StockOptionModificationAsPartOfRestructuring
1788000
CY2020Q3 sage Allocated Share Based Compensation Expense Including Restructing
AllocatedShareBasedCompensationExpenseIncludingRestructing
20108000
CY2019Q3 sage Allocated Share Based Compensation Expense Including Restructing
AllocatedShareBasedCompensationExpenseIncludingRestructing
43669000
sage Allocated Share Based Compensation Expense Including Restructing
AllocatedShareBasedCompensationExpenseIncludingRestructing
75250000
sage Allocated Share Based Compensation Expense Including Restructing
AllocatedShareBasedCompensationExpenseIncludingRestructing
122552000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.03
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20108000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
43669000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
37.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
99.49
us-gaap Net Income Loss
NetIncomeLoss
-368822000
us-gaap Net Income Loss
NetIncomeLoss
-511585000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51981468
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51704687
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51938923
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50496489
CY2020Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2019Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51981468
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51704687
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51938923
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50496489
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.48
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.10
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.13
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7451326
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7451326
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7096222
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7096222
CY2020Q2 sage Operating Expenses Workforce Reduction Percentage
OperatingExpensesWorkforceReductionPercentage
0.53
us-gaap Restructuring Charges
RestructuringCharges
27873000
us-gaap Payments For Restructuring
PaymentsForRestructuring
24079000
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
2438000
CY2020Q3 us-gaap Restructuring Reserve
RestructuringReserve
1356000

Files In Submission

Name View Source Status
0001564590-20-050861-index-headers.html Edgar Link pending
0001564590-20-050861-index.html Edgar Link pending
0001564590-20-050861.txt Edgar Link pending
0001564590-20-050861-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gidzru35fw2v000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sage-10q_20200930.htm Edgar Link pending
sage-10q_20200930_htm.xml Edgar Link completed
sage-20200930.xsd Edgar Link pending
sage-20200930_cal.xml Edgar Link unprocessable
sage-20200930_def.xml Edgar Link unprocessable
sage-20200930_lab.xml Edgar Link unprocessable
sage-20200930_pre.xml Edgar Link unprocessable
sage-ex311_10.htm Edgar Link pending
sage-ex312_9.htm Edgar Link pending
sage-ex321_6.htm Edgar Link pending
Show.js Edgar Link pending